GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Average Rating of “Moderate Buy” by Brokerages

GoodRx Holdings, Inc. (NASDAQ:GDRX) has received a consensus rating of “Moderate Buy” from the fifteen research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $8.86.

A number of equities research analysts have issued reports on GDRX shares. UBS Group decreased their target price on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a research note on Friday, August 9th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 target price on shares of GoodRx in a research report on Friday, August 16th. Barclays reduced their price target on GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Monday, November 11th. Raymond James raised shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price objective on the stock in a research report on Friday, August 9th. Finally, Citigroup decreased their target price on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th.

Insider Activity at GoodRx

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 4.17% of the company’s stock.

Hedge Funds Weigh In On GoodRx

Hedge funds and other institutional investors have recently made changes to their positions in the business. American Century Companies Inc. acquired a new position in GoodRx in the second quarter worth about $18,183,000. Point72 Asset Management L.P. acquired a new position in shares of GoodRx in the 3rd quarter worth approximately $11,295,000. Rubric Capital Management LP raised its holdings in shares of GoodRx by 76.5% in the 2nd quarter. Rubric Capital Management LP now owns 3,736,802 shares of the company’s stock worth $29,147,000 after buying an additional 1,619,748 shares in the last quarter. Millennium Management LLC lifted its position in shares of GoodRx by 36.5% during the 2nd quarter. Millennium Management LLC now owns 4,121,939 shares of the company’s stock worth $32,151,000 after buying an additional 1,102,758 shares during the period. Finally, Pier Capital LLC acquired a new stake in GoodRx in the 3rd quarter valued at $3,259,000. 63.77% of the stock is owned by institutional investors.

GoodRx Stock Performance

GDRX stock opened at $4.76 on Wednesday. The firm has a 50 day simple moving average of $6.11 and a 200 day simple moving average of $7.29. GoodRx has a 52 week low of $4.09 and a 52 week high of $9.26. The stock has a market cap of $1.81 billion, a P/E ratio of -158.67, a P/E/G ratio of 3.57 and a beta of 1.39. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.